This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
Endovastec respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking "Save", only the cookies you selected will be used. You can with draw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.
Stock Code
688016.SH
Company News
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Endovastec™ Announces Annual Results for 2025: Solid Growth with Continued Innovation and Global Expansion
30 Mar 2026
The Company continued to advance its dual strategic of innovation-driven growth and global expansion, maintaining steady and positive business performance.
FDA Grants Breakthrough Device Designation to Endovastec™’s Hector™ Multi-Branch Thoracic Stent Graft System
13 Mar 2026
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Hector™ Multi-Branch Thoracic Stent Graft System (“Hector™”), an investigational device designed for the endovascular treatment of complex aortic arch disease.
Endovastec™ Completes First Commercial Use of Minos™ in the Netherlands
26 Sept 2025
Endovastec™ recently announced the first two commercial uses of its Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™) in the Netherlands.
Endovastec™’s Cratos™ Completes First Commercial Use in Hungary
12 Sept 2025
Endovastec™ recently announced the first commercial use of its Cratos™ Thoracic Branch Stent Graft System (Cratos™) in Hungary. The procedure was performed by Dr. Gabor Kasza, Dr. Gabor Fazekas, and their team at University of Pecs Medical School in Pecs, Hungary.
Endovastec™ Completes First Commercial Implantation of Minos™ in Ecuador and Hercules™-LP in Malaysia
06 Aug 2025
Recently, Endovastec™ achieved two notable milestones in the aortic and peripheral vascular fields.
Endovastec™’s Minos™ Completes First Commercial Implantation in Kazakhstan
16 Jul 2025
Endovastec™ announced the first commercial implantation of its Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™) in Kazakhstan. This marks the latest addition to the company’s product portfolio in this region, following of its Castor™ Branched Aortic Stent Graft System.
Endovastec™ Completes the First Batch of Commercial Uses of Next-Generation Cratos™
27 Jun 2025
Recently, the next-generation Cratos™ Branched Aortic Stent Graft System (Cratos™), developed by Endovastec™, was successfully used in two post-market clinical implantations at Zhongshan Hospital Fudan University, performed by Professors Weiguo Fu and Lixin Wang, and their team. These procedures mark a key milestone in the commercial clinical application of Cratos™ in China, following its regulatory approval in March 2025.
Endovastec™’s Talos™ Completes First Commercial Use in Argentina
20 Jun 2025
Endovastec™ recently announced the first commercial use of its Talos™ Thoracic Stent Graft System (Talos™) in Argentina. The procedure was performed by Dr. Marcelo Bettinotti, Dr. Sebastian Peralta, and their team at Sanatorio Güemes Hospital in Buenos Aires, Argentina.
Endovastec™ Completes First Implantation of Minos™ in Malaysia
10 Jun 2025
The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™), developed by Endovastec™, was recently used in its first post-market implantation in Malaysia.
Endovastec™’s Talos™ Completes First Commercial Use in South America
23 May 2025
Endovastec™ is proud to announce the first successful clinical implantation of its Talos™ Thoracic Stent Graft System (Talos™) in South America. The procedure was performed by Prof. Bruna de Fina, Dr. Henrique Elkis, Dr. Guilherme Centofanti, and their team from Samaritano Paulista Hospital in São Paulo, Brazil.
Endovastec™’s Minos™ Receives CE MDR Certification and Gains Market Approval in Egypt
15 May 2025
The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™), developed by Endovastec™, recently received CE MDR (Medical Device Regulation (EU) 2017/745) certification and market approval in Egypt - a milestone in its global market expansion.
Endovastec™’s Castor™ Achieves First Clinical Use in Multiple Countries, Including Singapore’s Debut of Its Fenestrated Variant
09 May 2025
Recently, the Castor™ Branched Aortic Stent Graft System (Castor™), developed by Endovastec™, completed its first implantations in Malaysia, Kazakhstan, and South Korea, making significant milestones in the product’s global clinical adoption. Additionally, the first implantation of its fenestration was recently performed in Singapore, expanding the device’s footprint in personalized endovascular care.
Endovastec™ Receives Market Approval for Talos™ in Brazil and Argentina
25 Apr 2025
Endovastec™ announced that its Talos™ Thoracic Stent Graft System (Talos™) has recently received marketing approval in Brazil and Argentina, marking an important milestone in the company’s global strategy and its commitment to improving patient access to advanced aortic therapies.
Endovastec™ Announces Annual Results for 2024: Global Expansion Accelerates as Innovation Drives Quality Development
28 Mar 2025
During the Reporting Period, the Company achieved revenue of RMB 1.206 billion, with a net profit attributable to shareholders of listed companies of RMB 502 million and basic earnings per share of RMB 4.07.
Endovastec™’s Hector™ Receives Fast-Track Registration for Innovative Medical Devices in China
07 Mar 2025
Recently, Endovactec™’s Hector™ Multi-Branch Thoracic Stent Graft System (Hector™) has been approved to enter the Special Review Procedures for Innovative Medical Devices by China’s National Medical Products Administration (NMPA).
Multiple Key Products from Endovastec™ Received Marketing Approval in Ecuador for the First Time
12 Feb 2025
Recently, several key aortic intervention products of Endovastec™ have been approved for registration in Ecuador.
Endovastec™ Completes Acquisition of European Medical Device Company Optimum Medical
26 Aug 2024
On August 26, 2024, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (hereinafter referred to as “Endovastec™”) announced the completion of its acquisition of 72.37% equity in its associate company Optimum Medical Device Inc. (hereinafter referred to as “Optimum Medical”), a European medical device company. With the closing of this transaction, Optimum Medical has now become a wholly-owned subsidiary of Endovastec™. Optimum Medical owns two subsidiaries, Lombard Medical Limited and Lombard Medical Technologies GmbH (collectively referred to as “Lombard Medical”).
Endovastec™’s Cratos™ Qualifies as EU Custom-Made Device
24 Aug 2024
Recently, the Cratos™ Thoracic Branch Stent Graft System (Cratos™), developed by Endovastec™, has achieved certification as a Custom-Made Device (CMD) in the EU.
Endovastec™ Announces Annual Results for 2023
27 Mar 2024
On 27 March, 2024, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™，Stock code: 688016.SH) announced the annual results of Endovastec™ and its subsidiaries (the Company) for the 12 months ended 31 December, 2023 (the Reporting Period).
Endovastec™ Completes Its First Implantation of Cratos™ in Pre-Market Clinical Study in the EU and Japan
19 Mar 2024
Recently, The Cratos™ Branched Aortic Stent-Graft System (Cratos™), developed by Endovastec™, completed its first pre-market implantation at the University Hospital Zurich in Switzerland, as the starting of its CREATION clinical study. This study is instrumental for approval applications in the EU and Japan.
Endovastec™’s Hector™ Multi-Branch Thoracic Aortic Stent-Graft Completed the First Clinical Implantation in Switzerland
29 Feb 2024
Recently, Endovastec™'s Hector™ Multi-Branch Thoracic Aortic Stent-Graft System (Hector™) completed its first clinical application in Switzerland.
Endovastec™ Completes Its First Implantation of Castor™ Branched Stent-Graft and Hercules™-LP Stent Graft in Singapore
16 Nov 2023
Recently, the first implantation of the Castor™ Branched Aortic Stent-Graft and Delivery System (Castor™ Branched Stent-Graft) and Hercules™ Thoracic Stent Graft with Low Profile Delivery System covered stent (Hercules™-LP Stent Graft) developed by Endovastec™, was completed at Tan Tock Seng Hospital by Professor Glenn Tan, Professor Pua Uei, Professor Lawrence Quek, and their team. This marks the first clinical use of Endovastec™’s products in Singapore.
Endovastec™ completes the first clinical implantation of Minos™ Stent Graft System in Azerbaijan
29 Aug 2023
Recently, Endovastec™’s Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™) was successfully implanted in the first clinical case at Baku Merkezi Hospital in Azerbaijan. The surgery was performed by Professor Kamuran Musayev and his vascular surgery team.
Endovastec™ Achieves Its First Clinical Implantation of Reewarm™ PTX DCB Catheter in Brazil
14 Aug 2023
Recently, Reewarm™ PTX Drug Coated Balloon (DCB) Catheter, developed by Endovastec™, has been successfully implanted for the first time in Brazil, showing the product’s continued proliferation in international markets to serve patients worldwide. Dr. Flávio Meireles, Dr. Pedro Vilas Boas, and their team at Paulo Sacramento Hospital in Sao Paulo, Brazil, completed this operation.
Endovastec™'s Three Products in the Aortic Intervention Field Have Been Approved in Thailand
14 Aug 2023
Recently, the Castor™ Branched Aortic Stent-Graft and Delivery System (Castor™ Branched Stent-Graft), the Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™ Stent-Graft), and the Hercules™ Thoracic Stent Graft System with Low Profile Delivery System (Hercules™ LP Stent Graft), developed by Endovastec™ have been granted registration approval from the Thailand Food and Drug Administration (TFDA). These three products are the key offerings from Endovastec™ in endovascular intervention for thoracic and abdominal aortic diseases.
Endovastec™ Receives Approval for the Minos™ Abdominal Aortic Stent-Graft and Delivery System in Singapore
31 May 2023
On May 17, 2023, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (referred to as "Endovastec™") received registration approval from the Health Sciences Authority of Singapore for its MinosTM Abdominal Aortic Stent-Graft and Delivery System (hereafter referred to as "Minos™ Stent-Graft System").
Endovastec™ participates in the Congresso International de Cirurgia Endovascular
26 May 2023
Recently, the 2023 International Congress of Endovascular Surgery (CICE) was held in Brazil, and Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) was invited to participate, set up an exhibition booth, and welcome domestic and international experts to participate in academic discussions.
Endovastec™ has Completed the First Clinical Cases of Two Products in Colombia
14 Apr 2023
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently completed their first successful cases of its HerculesTM Thoracic Stent Graft with Low Profile Delivery System (hereinafter referred to as "HerculesTM -LP Stent Graft") and MinosTM Abdominal Aortic Stent Graft and Delivery System (hereafter referred to as “MinosTM Stent Graft System”) in Colombia, marking the official entry of Endovastec™'s products into the Colombian market.
Endovastec™ Received Approval for Hercules™ -LP Thoracic Stent Graft in Singapore
14 Apr 2023
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently received registration approval from the Health Sciences Authority (HSA) of Singapore for its HerculesTM Thoracic Stent Graft with Low Profile Delivery System covered stent (hereafter referred to as "Hercules TM -LP Stent Graft").
Endovastec™ Announces Annual Results for 2022
29 Mar 2023
On March 29, 2023, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH, hereafter referred to as “Endovastec™”) announced the annual results of Endovastec™ and its subsidiaries (hereafter referred to as the “Company”) for the 12 months ended December 31, 2022 (hereafter referred to as the “Reporting Period”). In the reporting period, the Company recorded revenue of RMB 897 million, representing an increase of 30.95% as compared to the corresponding period of last year; the net profit attributable to shareholders of listed companies after deducting the losses of associated companies and equity incentives was RMB 383 million, representing an increase of 21.20% compared to the corresponding period of last year; the net profit attributable to shareholders of listed companies stood at RMB 357 million, an increase of 12.99% compared to the corresponding period of last year.
First Implantation of Endovastec™'s Castor™ Branched Aortic Stent-Graft System Completed in Netherlands
31 Jan 2023
The first implantation of the Castor™ Aortic Branched Stent-Graft and Delivery System (Castor™) developed by Endovastec™ has been successfully completed in Netherlands. This marks the product’s 11th global market debut, following the United Kingdom, Poland, Spain, Argentina and others. The procedure was performed by a team led by Professor Kak Khee Yeung of Amsterdam University Hospital.
Endovastec™ Completes First Pre-market Clinical Implantation of TIPS Stent Graft System
18 Nov 2022
Intervastec™, a subsidiary of Endovastec™, has officially launched a clinical study of its independently developed Transjugular Intrahepatic Portosystemic Shunt (TIPS) Stent Graft System at Zhongshan Hospital of Fudan University (Zhongshan Hospital). The clinical study will be led by its principal investigator Zhiping Yan, who is the Director of the Department of Interventional Therapies at Zhongshan Hospital. Recently, the first pre-market clinical implantation of the TIPS Stent Graft System was successfully completed in Rui’an People's Hospital by Prof. Changsheng Shi and his interventional vascular surgery team.
Groundbreaking Ceremony for Endovastec™ Global Headquarters and Innovation & Industrialization Base Project Successfully Held
17 Oct 2022
On October 17, 2022, the groundbreaking ceremony for the Global Headquarters and the Innovation & Industrialization Base Project of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”, stock code: 688016.SH) was successfully held in Shanghai International Medical Zone (SIMZ), Zhangjiang Science City, Pudong District of Shanghai.
Endovastec™ Minos™ Abdominal Aortic Stent-Graft and Delivery System Receives Approval for Marketing in South Korea
02 Sept 2022
Endovastec™ has received registration approval from the Ministry of Food and Drug Safety of Korea (MFDS) for its independently developed Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™ Stent Graft System). This is the first time the Minos™ Stent Graft System has received marketing approval in an overseas market in Asia. The Minos™ Stent Graft System was approved for marketing in China in 2019 and received the CE marking in the same year. Since its approval, the Minos™ Stent Graft System has been available in 14 markets, including China, Greece, the United Kingdom, Poland, Germany, Brazil, and Argentina.
Endovastec™ Minos™ Abdominal Aortic Stent-Graft and Delivery System Receives Approval for Marketing in Colombia
02 Sept 2022
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently received registration approval from the Colombian National Institute for Drug and Food Surveillance (INVIMA) for the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ System”). Colombia becomes the third Latin American country to approve the Minos™ System, after Brazil and Argentina. The Minos™ System obtained CE marking in 2019 and has been available in 12 overseas markets including Greece, Poland, the United Kingdom, Germany, Argentina, Brazil and other countries.
Endovastec™ Announces 2022 Interim Results
25 Aug 2022
Shanghai, China, 25 August 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) today announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the “Reporting Period”).
Endovastec™ Reewarm™ PTX DCB PTA Catheter Receives Marketing Approval in Brazil
05 Jul 2022
Brasilia, Brazil, 4 July 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) today announced that it has received registration approval from the Brazilian Health Regulatory Agency (ANVISA) for its independently developed Reewarm™ paclitaxel (PTX) drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) Catheter (“Reewarm™ PTX”).
Endovastec™ Presents Flagship Products at CICE 2022
04 Jul 2022
Recently, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) held a seminar at the International Congress of Endovascular Surgery (Congresso International de Cirurgia Endovascular, CICE 2022) in Brazil, engaging local and global experts.
Endovastec™ Holds Virtual Launch Meeting for Fontus™ Branched Surgical Stent Graft System
28 Apr 2022
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently hosted a product launch event titled “Elephant trunk for the heart: revival of the classic” for its Fontus™ Branched Surgical Stent Graft System (Fontus™), which was held back-to-back with a seminar on the stented elephant trunk procedure. Twenty-one experts from 17 hospitals gathered virtually to share clinical data and information related to the application of Fontus™, which attracted the attendance of over 5,000 viewers online.
Endovastec™ Receives MDSAP Certificate for Brazil and Japan
08 Apr 2022
Shanghai, China, 11 April 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received a Medical Device Single Audit Program (MDSAP) certificate from the Technischer Überwachungs-Verein (TÜV SÜD), an international notified body, certifying Endovastec™’s compliance with both ISO13485:2016 standards and the regulatory requirements in Brazil, and Japan, which lays the groundwork and provides the momentum for the company's global development.
Endovastec™ Announces Annual Results for 2021
31 Mar 2022
Shanghai, China, 29 March 2022 - Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (hereafter referred to as "Endovastec™" or the “Group”) today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021 (hereafter referred to as the "Reporting Period"). In the reporting period, the Group recorded revenue of RMB 685 million, representing an increase of 45.59% as compared to the corresponding period of last year, with the net profit RMB 363 million, representing an increase of 45.15%. The net profit attributable to shareholders was RMB 316 million with an increase of 47.17%. The net profit excluding non-recurring gains and losses was RMB 289 million, an increase of 51.08%.
Hyperflex® Balloon Catheter by Endovastec™ Receives Marketing Approval in Japan
19 Mar 2022
Tokyo, Japan, 24 March 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received registration approval from Japan Pharmaceuticals and Medical Devices Agency (PMDA) for its independently-developed Hyperflex® Balloon Catheter (Hyperflex®) as the company’s first product approved for marketing in Japan. Hyperflex® obtained CE Mark in 2016 and is already available in overseas markets in South America and Asia.
First Clinical Implantation of Endovastec™’s Hercules®-LP Thoracic Stent Graft System Completed in India
03 Mar 2022
Kochi, India - Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has completed the first clinical implantation of its independently developed Hercules® Low Profile Thoracic Stent Graft and Delivery System (Hercules®-LP Stent Graft System) in India. This is the first product from Endovastec™ which has been approved for marketing and used in a clinical setting in India, the thirteenth market for the Hercules®-LP Stent System, following China, Brazil, Italy, the United Kingdom, and Turkey.
Endovastec™ Talos™ Thoracic Stent Graft System Receives NMPA Approval for Marketing
12 Jan 2022
Shanghai, China—Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received a registration certificate from China’s National Medical Products Administration (NMPA) for its independently developed Talos™ Thoracic Stent Graft System (Talos™).
Endovastec™ Debuts at Pan-American Congress on Vascular and Endovascular Surgery
15 Oct 2021
Rio de Janeiro, Brazil—Recently, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”), debuted at the XVI Pan American Congress on Vascular and Endovascular Surgery (PAN 2021) with two flagship products, the Castor™Branched Aortic Stent-Graft System (“Castor™ Stent”) and the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”). As the most prestigious and authoritative congress for endovascular surgery in Latin America, the online congress was attended by about 40 experts to discuss various hot topics related to aortic aneurysm, aortic arch, aortoiliac occlusive disease, subinguinal and distal venous thrombosis, COVID-19 complications, varicose vein surgery, and carotid artery surgery, among others.
Clinical Trial Enrollment Completed for the First Endovastec™ Venous Stent
10 Oct 2021
Beijing, China—The final procedure of the pre-market multicenter clinical trial for the Vflower® Venous Stent System, a braided venous stent independently developed by Shanghai MicroPort Endovascular MedTech （Group）Co., Ltd. (“Endovastec™”), a subsidiary of MicroPort Scientific Corporation (00853.HK), was recently completed, marking the completion of enrollment in this program. The clinical trial for the Vflower® Venous Stent System is a prospective, multi-center, single-arm nationwide clinical study led by Peking Union Medical College Hospital in conjunction with The Affiliated Hospital of Qingdao University and 12 medical centers as co-participators in China. It took only 10 months from the first implantation to the enrollment completion.
Products Complete First Implantations in the UK Following Endovastec’s Entry into the UK Market
03 Sept 2021
Hull and Doncaster, United Kingdom—Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), announced recently that the first implantations of the Castor™ Branched Aortic Stent-Graft System (“Castor™ Stent”), Hercules™ Low Profile Thoracic Stent Graft and Delivery System (“Hercules™-LP Stent Graft System”) and the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”) have been successfully completed in the United Kingdom. The UK is the sixth overseas market where the Castor™ Stent is available, after Poland, Spain, Argentina, Italy and Brazil, is the ninth overseas market for the Hercules™-LP Stent Graft System, after Argentina, Brazil, Poland, Georgia, Italy, Spain, Germany and Turkey, and is the twelfth overseas market for the Minos™ Stent Graft System, after Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia, Hungary, Brazil and the Czech Republic.
Endovastec™ Minos™ Stent Graft System Completes First Clinical Implantation in Czech Republic
02 Aug 2021
Prague, Czech Republic—The first implantation of the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”), a product self-developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”), was completed in the Czech Republic. This marks the eleventh overseas market that the Minos™ Stent Graft System has entered, after Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia, Hungary and Brazil.
Endovastec™ Received ISO 50001 Energy Management System Certificate
02 Aug 2021
Shanghai, China - Shanghai MicroPort Endovascular MedTech （Group）Co., Ltd. (Endovastec™), has obtained the ISO 50001:2018 Energy Management System Certificate after passing the assessment by the Conformity Assessment Certification Body. To date, Endovastec™ has developed an increasingly comprehensive management system after having passed a series of system certifications including for quality management, environmental management, occupational health and safety management, brand cultivation management, and intellectual property management, as well as the CNAS (China National Accreditation Service for Conformity Assessment) laboratory certification.
Endovastec™ Successfully Held First International TEVAR MasterClass
13 Jun 2021
Beijing, China—Recently, Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), successfully held the first International Thoracic Endovascular Aortic Repair (TEVAR) MasterClass. This online class invited ten experts from China and Europe, including Professor Chang Shu, Director of the Vascular Surgery Center of Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases and Prof. Franco Grego, the incumbent President of the European Society of Cardiovascular Surgery (ESCVS) and Director of Vascular Surgery Department at Padua University Hospital. During the Masterclass, the experts conducted in-depth exchanges and discussions on the cutting-edge developments and academic insights on TEVAR. More than a hundred participants watched the live streaming and participated in discussions online.
Endovastec™ Joined ICARUS 2021 Symposium
05 Jun 2021
Warsaw, Poland—Recently, Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), participated in the 2021 Interventional Endovascular Case Review European Symposium (ICARUS) at the invitation of the organizers.
First Implantation of Endovastec™ Minos™ Completed in Brazil
05 Jun 2021
São Paulo, Brazil—Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”), a product developed by Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), was used in Brazil for the first time in a recently completed case. This marks the tenth overseas market that the Minos™ Stent Graft System has entered, after Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia and Hungary.
Endovastec™ Gained NMPA Approval for Minos™Abdominal Aortic Stent-Graft and Delivery System
25 Mar 2021
Shanghai MicroPort Endovascular MedTech Co., Ltd.（Endovastec™）recently announced that it has gained China NMPA (National Medical Products Administration) approval for its in-house developed Minos™Abdominal Aortic Stent-Graft and Delivery System (Minos™), which marked a formal clearance for entering the Chinese market.
First Implantation of Endovastec™ Castor™ Completed in Argentina
05 Mar 2021
Tandil, Argentina—The first implantation of the Castor® Branched Aortic Stent-Graft System (the “Castor™ Stent”) developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (00853.HK), was completed in Argentina, marking the product’s presence in the third overseas market after Poland and Spain, and the first one in South America.
Endovastec™ Castor™ Debuted at the First eCICE Conference in Brazil
19 Sept 2020
São Paulo, Brazil, 30 October 2020 — The first virtual International Congress of Endovascular Surgery (eCongresso Internacional de Cirurgia Endovascular (eCICE)) kicked off as an online event from 7 – 8th September, 2020. As an influential conference in Latin America in the field of vascular surgery, the congress brought together vascular surgeons from around the world to showcase recent academic insights and developments in several cutting-edge application areas of endovascular treatment. Castor™ Branched Aortic Stent-Graft System (the “Castor™ Stent”), the world’s first stent system of the kind developed by Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), was launched on eCICE's live case demonstration.
Reewarm™ PTX Drug Coated PTA Balloon Catheter Received EU CE Marking Certification
14 Dec 2020
Shanghai, China—Reewarm™ PTX Drug Coated PTA Balloon Catheter (“Reewarm™ PTX DCB Catheter”) developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) has recently obtained the CE Marking certification issued by the European Union. Previously, the product has received the registration certificate issued by China’s National Medical Products Administration (NMPA) in April 2020.
Endovastec™ Minos™ Completed First Clinical Implantation in Hungary
14 Dec 2020
Debrecen, Hungary—The Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”), which is developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) and now available in nine overseas markets, successfully completed its first implantation in Hungary in a recent operation.
Endovastec™ Accredited as“Shanghai Enterprise Technology Center”
27 Nov 2020
Shanghai, China—Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (Endovastec™) was accredited as a “Shanghai Enterprise Technology Center” for its outstanding performance in developing technical talents and efforts in technological innovation, in the 2020 list of Municipal Enterprise Technology Centers in Shanghai (batch 26) recently released by Shanghai Municipal Economy and Information Technology Commission (SHEITC).
Endovastec™ Castor™ Entered First Overseas Market
23 Nov 2020
Szczecin, Poland, December 11, 2020 — The first implantation of the Castor™ Branched Aortic Stent-Graft and Delivery System (“Castor™”), developed by Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (“Endovastec™”), was successfully completed in Poland in 29 October. Castor™ is the world’s first stent-graft system for simultaneous aorta and aortic arch repair through minimally invasive treatment.
speX Support Catheter Obtained NMPA Registration Certificate
10 Nov 2020
Shanghai, China—The speX Support Catheter distributed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received a registration certificate from the National Medical Products Administration (NMPA).
Endovastec™ Completed the First Implantation for Minos™ in Argentina
09 Nov 2020
Buenos Aires, Argentina – Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently successfully completed the first case for its Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”) in Argentina. It is the seventh international market outside of China where Minos™ Stent Graft System has entered after Greece, Poland, Spain, Germany, Italy and Switzerland, also the first country in South America.
Endovastec™ Completed the First Implantation of Minos™ in Spain
17 Jul 2020
Barcelona, Spain——July 15th, 2020. The Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”), which is produced by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), was successfully implanted in a patients with abdominal aortic aneurysm (AAA) in Spain. Spain is the third overseas market of Minos™ Stent Graft System after Greece and Poland.
Endovastec™ Completed the First Implantation of Minos™ in Poland
12 Jun 2020
Opole, Poland — June 8th, 2020. The Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”), which is produced by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), was successfully implanted in three patients with abdominal aortic aneurysm (AAA) in Poland. Poland is the second overseas market of Minos™ Stent Graft System after Greece.
Endovastec™ Completed the First Implantation of Minos™ Outside of China
04 Mar 2020
Thessaloniki, Greece – The Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™”), which is produced by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), was successfully implanted in a patient with abdominal aortic aneurysm (AAA) in Greece recently. Professor Georgios A. Pitoulias from General Hospital of Thessaloniki “G. Gennimatas - Agios Dimitrios” was the first expert in Europe to try this product. The case marked the first implantation of Minos™ Stent Graft System outside of China since the device received CE Mark in September 2019.
Endovastec™ Won 2019 Shanghai Municipal Quality Management Prize
02 Mar 2020
Shanghai, China – Shanghai MicroPort Endovascular MedTech Co., Ltd. ("Endovastec™") was recently awarded the 2019 Shanghai Municipal Quality Management Prize ("Prize"). The winners of the Prize were announced after the procedure including formal review, dossier assessment, panel review, on-site verification, result approval and online pre-release.
Endovastec™ Won "Pudong New Area Quality Gold Prize”
10 Jan 2020
Shanghai, China – Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) was recently awarded the “Pudong New Area Quality Gold Prize” (“the Prize”) after a panel announced the results of the panel review and public inputs done for the 3rd Pudong New Area Government Quality Prizes.
Minos™ Entered 2019 Shanghai Municipality Recommendation Directory for Innovative Products
04 Dec 2019
Shanghai, China – Shanghai Municipal Commission of Economy and Informatization published the 2019 Shanghai Municipality Recommendation Directory for Innovative Products recently. The Minos™ Ultra-Low Profile Abdominal Aortic Aneurysm Stent Graft System (“Minos™ Stent Graft”), which is self-developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), was successfully granted entry into the directory.
A Patent of Hercules™-LP Won Shanghai Intellectual Property Innovation Award
08 Nov 2019
Shanghai, China – Recently, results of Shanghai Intellectual Property Innovation Award were released. This activity was carried out jointly by Shanghai Municipal Bureau of human resources and social security, Shanghai Intellectual Property Administration. A patent named Stent-Graft System and its usage of Hercules™ Low-Profile Thoracic Stent-Graft System（“Hercules™-LP”）,which belongs to Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”), won second prize of patent and trademark in the Shanghai Intellectual Property Innovation Award with its cultivation, transformation and industrialization of high-value intellectual property. Endovasctec™ was awarded the Shanghai Patent Work Pilot Enterprise in 2017.
Minos™ was Selected as Shanghai innovative Biomedical Products in 2018-2019
12 Oct 2019
Shanghai, China——On September 30, 2019, Shanghai Science and Technology Commission published a publicity list of the results of the evaluation of Shanghai innovative biomedical products in 2018-2019. And Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ Stent Graft System”) independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”) was successfully selected. Minos™ Stent Graft System was Approved special medical device approval process in 2017, gained NMPA approval in March and CE certificate in September 2019. And its post-marketing clinical study was selected for the 2019 “Science and Technology Innovation Action Plan” project in the field of cooperation between industry, education, research and medicine in Shanghai.
Endovasctec™ Won the 2019 Shanghai Key Product Quality Research Achievement Award
12 Oct 2019
Shanghai, China——On September 30, 2019, Shanghai Administration Bureau of Market Supervision and Shanghai Municipal Economic and Information Commission co-organized an exchanging meeting of the 2019 Shanghai key product quality research work experience, which announced the results of the 2019 Shanghai key product quality research projects and individuals. Industrialization upgrading project of Hercules™ Low Profile Thoracic Stent-Graft System was awarded the third prize of the 2019 Shanghai key product quality research achievement award for its technological innovation and industrial management advantages.
The Post-marketing Clinical Study of Minos™ was Selected for 2019 “Science and Technology Innovation Action Plan” Project in the Field of Cooperation
30 Sept 2019
Shanghai, China——As a clinical demonstration application research topic for innovative medical devices, the post-marketing clinical study of Minos™ Abdominal Aortic Stent-Graft and Delivery System, which was co-declared by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”), Zhongshan Hospital of Fudan University and Renji Hospital of Shanghai Jiaotong University, was selected for the 2019 “Science and Technology Innovation Action Plan” project in the field of cooperation between industry, education, research and medicine in Shanghai.
Minos™ Gained CE Certificate
17 Sept 2019
Shanghai, China——Minos™ Abdominal Aortic Stent-Graft and Delivery System ( “Minos™”) independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”) successfully gained CE certificate on September 12, 2019. It is the third CE certificate product following the Hercules™ Balloon Inflation Catheter and Reewarm™ PTA Balloon Dilatation Catheter, and the first CE certificate for the aortic stent graft products.
“Beyond the Road, Aortic Forum" International Aortic Forum Series Report
01 Sept 2019
Shanghai, China – Recently, the 4th “Beyond the Road, Aortic Forum” was successfully held by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”, or “the Company”). There are 11 doctors from Argentina participated in this forum. Under the support from the top clinical centers on the field of aortic disease treatment in China, this forum aims to provide a long-term learning and communication platforms for overseas doctors in cardiac surgery and vascular surgery.
Endovastec™ was Listed on the STAR Market of the Shanghai Stock Exchange
22 Jul 2019
Shanghai, China - Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”, or “the Company”) was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019, becoming one of few medical device companies in the first batch of 25 companies to be listed on the market.
"Hercules®" Trademark Granted Entry into the List of the Third Batch of Major Protected Trademarks of Shanghai Municipality
05 Feb 2019
Shanghai, China - The Shanghai Municipal Administration of Market Regulation recently published the List of the Third Batch of Major Protected Trademarks of Shanghai Municipality (“the List”). The “Hercules®” trademark of Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) was granted the entry into the List and rated as one of the third batch of Major Protected Trademarks of Shanghai Municipality.
Attends National Continuing Education Classes of China Endovascular Course 2018 (CEC2018)
19 Jan 2019
Shanghai, China – The National Continuing Education Classes of China Endovascular Course 2018 (CEC 2018) was recently held at the Shanghai International Convention Center in Shanghai, China. The event was jointly organized by Zhongshan Hospital Affiliated to Fudan University, Beijing Anzhen Hospital of Capital Medical University, Chinese PLA General Hospital, Cross-Strait Medicine Exchange Association, and China Research Hospital Association, with the attendance of nearly 4,000 Chinese and overseas cardiologists. Shanghai MicroPort Endovascular MedTech Co., Ltd. ("Endovastec™") presented at CEC 2018 the products of Castor® Branched Aortic Stent-Graft System ("Castor®"), Minos™ Ultra Low-Profile Stent Graft System ("Minos™"), and Reewarm™ PTX Drug Coated Balloon (Reewarm™).
Castor™ Granted Entry into the 2018 Shanghai Municipality Innovative Product Recommendation List
11 Jan 2019
Shanghai, China – Recently, Shanghai Municipal Commission of Economy and Informatization published the 2018 Shanghai Municipality Innovative Product Recommendation List (“the Recommendation List”). The Castor™ Branched Aortic Stent-Graft System ("Castor™"), which was independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (Endovastec™), was granted entries into the list.
Castor™ Included in "2018 Shanghai Innovative Product Recommendation List"
01 Dec 2018
Shanghai, China——Recently, Shanghai Municipal Commission of Economy and Informatization released the “2018 Shanghai Innovative Product Recommendation List”(Recommendation List). The product in-house developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”), Castor Branched Aortic Stent-Graft System (“Castor”) was successfully selected. Castor launched in June of 2017 after it Entered “Green Path”in 2015.
Endovastec™ Selected as "2018 Shanghai Science and Technology Little Giant Enterprise"
01 Nov 2018
Recently， Shanghai MicroPort Endovascular MedTech Co., Ltd.( Endovastec™) was listed as “2018 Shanghai Science and Technology Little Giant Enterprise”. In future, the selected companies will gain funding from city or district (county) governments based on the companies' independent innovation plans.Before then, MicroPort® Endovascular was successfully Selected as “2016 Shanghai Science and Technology Little Giant Enterprise(for Cultivation)”, and passed the project acceptance inspection in 2018.
MicroPort® Endovascular Held the 3rd “Beyond the Road” Aortic Forum
31 Oct 2018
Recently, the 3rd “Beyond the Road” Aortic Forum was successfully held by Shanghai MicroPort® Endovascular MedTech Co., Ltd. (hereinafter referred to as MicroPort® ENDO). The forum, on the basis of the top clinical centers for aortic disease surgical repairs in China, aims to provide a permanent didactic and exchange platform for overseas surgeons from the regions in and beyond the coverage of the Belt and Road Initiative. 8 experts from Argentina participated in this forum.
MicroPort® Endovascular Awarded 2017 Shanghai Brand Cultivation Demonstration Enterprise
12 Sept 2018
Shanghai, China – On April 9, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was awarded "2017 Shanghai Brand Cultivation Demonstration Enterprise" by Shanghai Municipal Commission of Economy and Information.
FONTUS™ Single-branched Stent Graft System in Surgical Operation Enters “Green Path”
15 Aug 2018
Shanghai, China - Recently, FONTUS™ Single-branched Stent Graft System in Surgical Operation (“FONTUS™”), which is independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (“MicroPort Endovascular”), has passed the review of China State Drug Administration (SDA) and entered the special review and approval procedure for innovative medical devices, which is also known as the Green Path.
MicroPort Endovascular Held “Beyond the Road” Aortic Forum
05 Jul 2018
Beijing, China - MicroPort Endovascular (Shanghai) Co., Ltd. (“MicroPort Endovascular”) recently held the first edition of the “Beyond the Road” Aortic Forum jointly with Professor Chang Shu, who is head of the cardiovascular surgery department of Fuwai Hospital of Chinese Academy of Medical Sciences. The forum, echoing China's Belt and Road Initiative, aims to provide a permanent didactic and exchange platform for overseas surgeons from the regions in the coverage of the Belt and Road Initiative and beyond on the basis of the top clinical centers for aortic disease surgical repairs in China. Professor Danilo Kuizon from St. Luke’s Medical Center and Heart Institute in the Philippines participated in the 4-day forum.
MicroPort® Endovascular Attended Lijiang Vascular Surgery Intervention Treatment Summit
08 May 2018
Guilin, China – From May 4 to May 6, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Second Guangxi Guilin Lijiang Vascular Surgery Intervention Treatment Summit and hosted a satellite meeting. The summit focused on the latest development and hot issues of vascular surgery by expert lectures, keynote speeches, as well as debates and discussions.
MicroPort® Endovascular Attended CICE 2018
20 Apr 2018
Sao Paulo, Brazil – MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the CICE 2018 held in Sao Paulo, Brazil and invited Professor Chang Shu of Fuwai Hospital to share his clinical experience and take part in academic exchange activities such as case demonstration and academic salons in Argentina and Dominican Republic.
MicroPort® Endovascular Hercules™ Series Products Gained Regulatory Approval in Colombia
08 Feb 2018
Bogota, Colombia - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") obtained the regulatory approval from Colombia's health authority INVIMA for its in-house developed Hercules™-T Low Profile Stent-Graft ("HT-LP"), Hercules™ Bifurcated Stent-Graft System and Delivery System, and Hercules™ Balloon Dilation Catheter. This is the first time for MicroPort® Endovascular's products to gain regulatory approval in Colombia. Previously, the three products have received approval in Brazil, Argentina, Peru, Thailand, Indonesia, and the Philippines.
MicroPort®Endovascular Gained its First State Science and Technology Progress Award
25 Jan 2018
Shanghai, China – On January 8, the project of "Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products", jointly developed by Shanghai MicroPort (Medical) Group Co., Ltd. ("MicroPort®"), its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), and Beijing Anzhen Hospital of Capital Medical University, won the second prize of State Science and Technology Progress Award. It is the first State Science and Technology Progress Award earned by MicroPort® Endovascular.
Altura™ Endograft System Granted CFDA Green-Path
09 Jan 2018
Shanghai, China – On December 6, Altura™ Endograft System ("Altura™"), distributed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort®Endovascular") and developed by UK-based Lombard Medical, Inc. ("Lombard Medical"), was granted to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices.
MicroPort® Endovascular Attended CEC 2017
01 Dec 2017
Beijing, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently attended the 10th China Endovascular Course & 2017 National Continuing Education Program for Vascular Surgeons ("CEC 2017") that was held in the Beijing National Convention Center, to broadcast surgeries as well as host satellite meetings and academic symposiums with experts in attendance. The CEC 2017 was hosted by Beijing Anzhen Hospital of Capital Medical University, Chinese PLA General Hospital, Zhongshan Hospital of Fudan University, and Cross-Straits Medicine Exchange Association. It aims to enhance the development of basic medicine, standardize clinical operation, follow up the results of major studies and researches, and display the latest advancement in the vascular disease treatment.
MicroPort® Endovascular's HT-LP Included in 2017 Shanghai Innovative Product Recommendation List
14 Nov 2017
Shanghai, China – Hercules™-T Low Profile Stent-Graft ("HT-LP"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was recently included in the 2017 Shanghai Innovative Product Recommendation List ("Recommendation List") according to an announcement recently released by Shanghai Municipal Commission of Economy and Informatization. Such honor is expected to benefit the commercialization and industrialization of HT-LP.
Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases Wins First Prize of Shanghai Science and Technology Progress Award
23 Oct 2017
Shanghai, China – On March 22, the Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases," jointly developed by Shanghai MicroPort (Medical) Group Co., Ltd ("MicroPort®"), its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), Beijing Anzhen Hospital of Capital Medical University, and Changhai Hospital of the Second Military Medical University, won the First Prize of Shanghai Science and Technology Progress Award.
MicroPort® Endovascular Hosted Product Launch of Castor™
15 Oct 2017
Shanghai, China – From October 12 to October 14, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Endovascology 2017 and hosted product launch of Castor™ Branched Aortic Stent-Graft System ("Castor™"). The conference aims to bring in the latest advancement and cutting-edge technology to China and to showcase the achievements in China's endovascular industry. More than 2,500 industry experts from over 40 countries including China, US, Canada, South Korea, Australia, and Egypt attended the congress to discuss about hot issues in the vascular surgery field worldwide.
First Post-market Implantation of Castor™ Successfully Completed
10 Oct 2017
Suzhou, China – The first post-market implantation of Castor™ Branched Aortic Stent-Graft System ("Castor™"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was recently successfully completed by Director Xiaoqiang Li of the Second Affiliated Hospital of Soochow University. The product gained the regulatory approval from China Food and Drug Administration in June 2017 to officially enter the China market.
Talos™ Gained CFDA Green-Path
28 Sept 2017
Shanghai, China – On September 27, Talos™ Thoracic Stent Graft System ("Talos™"), self-developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was approved to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices. The Green-Path will significantly expedite the approval time and meanwhile it demonstrated the recognition of Chinese government authorities in Talos™.
MicroPort® Endovascular Listed as 2017 Shanghai Patent Affairs Pilot Enterprise
12 Sept 2017
Shanghai, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was recently listed as "2017 Shanghai Patent Affairs Pilot Enterprise" by Shanghai Intellectual Property Administration and will receive fund from Shanghai government and Pudong district government. Shanghai Intellectual Property Administration started to accept applications of patent demonstration/pilot enterprises since February and selected 95 companies as "2017 Shanghai Patent Affairs Pilot Enterprises" after expert review, group discussion, and authority approval.
MicroPort® Hosted Ninth Aortic Intervention International Forum
28 Aug 2017
Shanghai, China – From August 21 to August 25, Shanghai MicroPort Medical (Group) Co., Ltd.("MicroPort®") hosted the 9th Aorta Intervention International Forum in three cities of China including Shanghai, Beijing and Changsha. During the forum, surgeons and distributors from Argentina and Dominican Republic were invited to visit Fuwai Hospital of Chinese Academy of Medical Sciences and the Second Xiangya Hospital of Central South University for academic exchange.
MicroPort® Endovascular Attended 2017 Vascular Intervention of Peking University
21 Aug 2017
Beijing, China – From August 17 to August 20, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 2017 Vascular Intervention of Peking University and hosted an academic salon themed on "'Ahead of the Arch' — a Discussion of the Endovascular Treatment Strategy for the Arch Disease." The conference provided an academic platform for clinicians to exchange ideas, solve puzzles and share knowledge.
MicroPort® and MicroPort® Endovascular Attended CHC 2017
15 Aug 2017
Beijing, China – From August 10 to August 13, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") and MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 2017 China Heart Congress ("CHC 2017") & the Second China Vascular Congress ("CVC") held in China National Convention Center of Beijing and hosted a satellite meeting. The congress was hosted by Chinese Medical Association and National Center for Cardiovascular Disease and was themed "Healthy Heart • Better Life: Innovation, Translation, and Cooperation."
MicroPort® Endovascular Attended the First Three Northeast Provinces Aortic Disease Interventional Treatment Summit
25 Jul 2017
Changchun, China – On July 22, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the First Three Northeast Provinces Aortic Disease Interventional Treatment Summit held in Changchun. Hosted by Chinese Association of Cardiovascular Surgeons and the First Hospital of Jilin University, the summit provided a platform for clinicians to exchange ideas on hot topics and difficult cases of aortic disease interventional treatment through typical case studies and special lectures.
MicroPort® Endovascular Attended SEC 2017
24 Jul 2017
Hangzhou, China – From July 6 to July 9, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 11th China Southern Endovascular Congress ("SEC") in Hangzhou, Zhejiang Province, and hosted two academic salons focusing on aortic arch treatment strategies and suitable stent structures for different kinds of aortic diseases. Around 2,000 experts from the vascular surgery field were gathered together to discuss hot topics extensively related with vascular diseases.
Reewarm™ Gained CFDA Approval
24 Jul 2017
Shanghai, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently obtained the regulatory approval from China Food and Drug Administration ("CFDA") for its in-house developed Reewarm™ PTA Balloon Catheter ("Reewarm™"). Reewarm® is designed to treat atherosclerosis-caused stenosis and occlusive disease in artery below groin, such as iliac artery, femoral artery, superficial femoral artery, popliteal artery, inferior genicular artery. It provides pre-expansion of the narrowed vascular lumen for future treatment.
MicroPort® Endovascular Attended SJVF-2017
11 Jul 2017
Shanghai, China – From June 23 to June 25, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Shanghai JiaoTong University Vascular Disease Forum ("SJVF-2017") held in Shanghai. Several renowned vascular surgery experts from home and abroad were invited to deliver speeches to reveal the latest achievement and the development trend of the vascular surgery industry in an all-round way while building a platform of communication for surgeons in attendance.
Castor™ Gained CFDA Approval
11 Jul 2017
Shanghai, China - Castor™ Branched Aortic Stent-Graft System ("Castor™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort®"), recently obtained the regulatory approval from China Food and Drug Administration ("CFDA"). It is the fourth device of MicroPort® that gained the CFDA approval through the CFDA Green Path for innovative medical devices.
MicroPort® Endovascular Attended VEC 2017
02 Jun 2017
Beijing, China – From May 12 to May 13, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Vascular and Endovascular Conference 2017 ("VEC 2017") in Beijing for academic exchange. The conference was hosted by China International Exchange and Promotion Association for Medical and Healthcare and Vascular Surgery Physicians Association of Beijing Medical Doctor Association. During the conference, domestic renowned vascular surgery specialists were gathered to share the latest advancement and development trend of China's vascular surgery industry.
MicroPort® Endovascular Attended Sixth Northwest Vascular Forum
08 May 2017
Xi'an, China – From May 5 to May 6, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Northwest Vascular Forum & the 12th Chang'an Vascular Forum held in Xi'an and held a satellite meeting of "the Application of Unibody Stent Design in Endovascular Repair." Hosted by the First Affiliated Hospital of Xi'an Jiaotong University, the meeting invited several renowned vascular surgery specialists from China and abroad to share all-around the latest advancement and the development trend of the vascular surgery field in China.
MicroPort® Endovascular was Listed as 2016 Shanghai Pudong New Area Enterprise Institution
21 Apr 2017
Shanghai, China – Shanghai Pudong New Area Technology and Finance Committee recently released the list of Enterprise R&D Institutions in Pudong New Area, and MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was listed among the 38 R&D institutions.
MicroPort® Endovascular Attended the Sixth Pangu Aortic Disease Forum
17 Apr 2017
Shenzhen, China – From April 14 to April 16, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Pangu Aortic Disease Forum held in Shenzhen, Guangdong Province. The forum, chaired by Professor Lizhong Sun of Beijing Anzhen Hospital of Capital Medical University, invited over 100 aortic specialists to have in-depth discussion on the new technology, new achievement, and new development of the aortic surgery.
MicroPort® Endovascular Attended 2017 Vascular Innovative Forum
03 Apr 2017
Beijing, China – On April 1, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 2017 Vascular Innovative Forum. The forum was hosted by the Vascular Device Branch of China Association for Medical Device Industry and the Special Committee of Vascular Medicine of Chinese Research Hospital Association, and organized by the Vascular Surgery Department of Chinese PLA General Hospital. The forum aims to provide a platform for clinical experts, policy makers, industry peers, and investors to exchange ideas on the cutting-edge technology and evidence-based medicine research related to the field of vascular diseases.
MicroPort® Endovascular Attended the Fifth Shandong (Mount Tai) Aortic Surgery Forum
13 Mar 2017
Jinan, China – On March 10, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Fifth Shandong (Mount Tai) Aortic Surgery Forum in Jinan, Shandong Province. The forum was mainly hosted by the Vascular Surgery Branch of Shandong Medical Doctor Association and the Vascular Surgery Branch of Shandong Medical Association, and organized by Shandong Provincial Hospital.
MicroPort® Endovascular Attended 8th Fuwai Aortic Diseases Treatment Symposium
16 Jan 2017
Beijing, China – From January 13 to January 15, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 8th Fuwai Aortic Diseases Treatment Symposium held in Beijing Fuwai Hospital, and displayed several devices including CRONUS™ Surgical Stent-Graft System ("CRONUS™"), Hercules™-T Low Profile Stent Graft and delivery system ("Hercules™-T"), and Castor™ Branched Aortic Stent Graft and delivery system ("Castor™").
MicroPort® Endovascular Awarded the Title of 2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative SMEs
11 Jan 2017
Shanghai, China – On January 9, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), the subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), was awarded the title of "2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative Small- and Medium-sized Enterprises ("SMEs")" by Shanghai Municipal Commission of Economy and Informatization.
Hercules™ was Awarded 2016 Shanghai Top-Brand Product
03 Jan 2017
Shanghai, China – On December 31, Hercules™ Stent Graft and Delivery System, in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was awarded 2016 Shanghai Top-Brand Product, according to a list released by Shanghai Top Brand Recommendation Committee of Shanghai Municipal Bureau of Quality and Technical Supervision. The award is to honor well-known products and brands with industry-leading position, high customer satisfaction and great development potential.
MicroPort® Endovascular Attended Sixth China Shenzhen International Cardiovascular Disease Forum China Cardiovascular Surgery Technique and Engineering Conference
20 Dec 2016
Shenzhen, China – From December 16 to December 18, MicroPort Endovascular (Shanghai) Co., Ltd.("MicroPort® Endovascular") attended the Sixth China Shenzhen International Cardiovascular Disease Forum & China Cardiovascular Surgery Technique and Engineering Conference in Shenzhen to display CRONUS™ Surgical Stent-Graft System ("CRONUS™") and other innovative products.
MicroPort® Endovascular Received CE Mark Approval for Hercules™ Inflation Catheter and Reewarm™ PTA Balloon Catheter
15 Dec 2016
Shanghai, China – On December 13, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") in-house developed Hercules™ Balloon Inflation Catheter and Reewarm™ PTA Balloon Catheter were both granted CE mark approval. It is the first CE mark approvals MicroPort® Endovascular has received, to successfully have its products registered in European Union countries, marking the first solid step to enter the European Union markets.
MicroPort® Endovascular was Selected as 2016 Shanghai Science and Technology Little Giant Enterprise (for Cultivation)
18 Nov 2016
Shanghai, China – On November 17, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") announced that its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was listed as "2016 Shanghai Science and Technology Little Giant Enterprise (for Cultivation)" by Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Commission of Economy and Informatization. The selected company will gain funding from city or district (county) governments based on the companies' independent innovation plans. Founded in 2010 and 2013 in Shanghai, MicroPort® Endovascular primarily focus on the development, manufacture, and marketing of the interventional medical devices respectively for the treatment of electrophysiological diseases, and peripheral-vascular- and endovascular-related diseases. Its device is widely used in China's top hospitals and has been exported to many overseas countries and regions. MicroPort® Endovascular was selected as 2015 Shanghai High- and New-Technology Enterprise.
MicroPort® Endovascular Attended the Ninth China Endovascular Course 2016 National Continuing Education Program for Vascular Surgeons
08 Nov 2016
Beijing, China – From November 3 to November 6, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Ninth China Endovascular Course & 2016 National Continuing Education Program for Vascular Surgeons ( "CEC 2016") that was held in the Beijing National Convention Center, to display its innovative products and host academic symposiums. CEC 2016 was hosted by Beijing Anzhen Hospital of Capital Medical University, Chinese PLA General Hospital, Zhongshan Hospital of Fudan University, and Cross-Straits Medicine Exchange Association.
MicroPort® Endovascular Received Outstanding Contribution to Performance Improvement Award of ISPI-China
02 Nov 2016
Beijing, China - On October 27, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was granted the "Outstanding Contribution to Performance Improvement Award" and its project "PLUS"（Portfolio Life-cycle United Stimulation）was granted the "Best Practice of Performance Improvement Award" by the International Society for Performance Improvement – China ("ISPI-China") in the 6th China Performance Improvement Forum held in Beijing. The forum aims to distribute the latest updates related with performance improvement and provides a platform for companies that stand out for performance improvement to share their experience and development stories.
MicroPort® Endovascular Attended ENDOVASCOLOGY 2016
17 Oct 2016
Shanghai, China – From October 13 to October 15, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the ENDOVASCOLOGY 2016 in Shanghai and hosted a satellite meeting for academic exchange on endovascular aortic repair ("EVAR"). The ENDOVASCOLOGY 2016 was hosted by Chinese Medical Doctor Association, Special Committee of Endovascology of Chinese Medical Doctor Association, and the Vascular Surgery Department of Changhai Hospital of the Second Military Medical University, with more than 2,000 experts and scholars from China, US, Europe, Australia, Japan and South Korea in attendance.
Minos™ Completed Patient Enrollment of Pre-market Clinical Trials
18 Sept 2016
Shanghai, China - Minos™ Ultra Low Profile Abdominal Aortic Aneurysm ("AAA") Stent-Graft and Delivery System ("Minos™ Ultra Low Profile AAA Stent-Graft"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), completed patient enrollment of pre-market clinical trials in assessing the safety and efficacy of Minos™ Ultra Low Profile AAA Stent-Graft in the treatment of AAA.
MicroPort® Endovascular Attended 13th Chinese Vascular Surgery Congress
16 Aug 2016
Chengdu, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently attended the 13th Chinese Vascular Surgery Congress of the Vascular Surgery Branch of Chinese Medical Association in Chengdu of Sichuan Province from August 11 to August 14, and displayed several innovative endovascular products. Around 1,000 domestic experts gathered together in the congress to dive deep into the application progress and prospect of drug, material, equipment and technique related with vascular surgery, with key note speeches on hot topics in the field of vascular surgery.
MicroPort® Awarded Shanghai Pudong New Area Top 20 Outstanding Contributor to Advanced Manufacturing Industry
29 Mar 2016
Shanghai, China – On March 29, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was awarded the Top 20 Outstanding Contributors to Advanced Manufacturing Industry of Shanghai Pudong New Area during the "2016 Awarding Ceremony of Outstanding Contributor to Economic Growth of Pudong New Area," fully demonstrating government authority's recognition of the achievements MicroPort® made in 2016.
Reewarm™ PTX Granted Green Channel Status for CFDA Approval
19 Feb 2016
MicroPort® Endovascular Attended 8th Fuwai Aortic Diseases Treatment Symposium
17 Jan 2016
Beijing, China – From January 13 to January 15, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 8th Fuwai Aortic Diseases Treatment Symposium held in Beijing Fuwai Hospital, and displayed several devices including CRONUS™ Surgical Stent-Graft System ("CRONUS™"), Hercules™-T Low Profile Stent Graft and delivery system ("Hercules™-T"), and Castor™ Branched Aortic Stent Graft and delivery system ("Castor™").
MicroPort® Endovascular Recognized as One of Shanghai's the First Group of High-tech Enterprise
20 Oct 2015
Shanghai, China -- recently, the Shanghai Municipal Office of Accreditation For Shanghai's High-tech Enterprises published a list of Shanghai's first batch of high-tech enterprises for year 2015. Shanghai MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular")was selected in the list, won the "high-tech enterprise" certificate, and will enjoy the benefit of the preferential policy that will deduct the income tax, equal to about 15% corporate income during the next three years. This recognition was jointly determined by the Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau, Shanghai Municipal State Tax Bureau and the Shanghai Municipal Bureau of Local Taxation, and announced to the public by the Shanghai Municipal High-tech Enterprises Identified Office.
Hercules™ Balloon Inflation Catheter Gained Market Launch Approval in Brazil
20 Aug 2015
MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular") recently gained the registration certificate for its in-house developed Hercules™ Balloon Inflation Catheter from Brazil's National Health Surveillance Agency.
MicroPort® Hosted 2015 Annual Distributor Conference
15 May 2015
Shanghai, China – 15 May, 2015 – Shanghai MicroPort Medical (Group) Co ("MicroPort") hosted 2015 Annual Distributor Conference on May 14 in its Shanghai headquarters to promote its products to nationwide distributors. About 400 distributors attended the meeting.
MicroPort® Endovascular Completed First Application of Reewarm™ PTX Drug Coated PTA Balloon Catheter
24 Mar 2015
Shanghai, China – 24 March, 2015 – MicroPort Endovascular (Shanghai) Co ("MicroPort Endovascular") recently successfully completed its first clinical application of Reewarm™ PTX Drug Coated PTA Balloon Catheter ("Reewarm™ PTX") in the middle segment of superficial artery. The Reewarm™ PTX clinical trial is a prospective, multi-center, single blind, randomized, controlled study, comparing drug coated balloon ("DCB") versus standard balloon angioplasty for the treatment of femoropopliteal arteries, which is expected to enroll 200 patients (1:1) in 11 centers in China.
MicroPort® Endovascular Released Six-month Follow-up Data of Castor™
09 Feb 2015
Shanghai, China – 9 February, 2015 – MicroPort Endovascular (Shanghai) Co ("MicroPort Endovascular") recently released the six-month follow-up data of its in-house developed Castor™ Branched Aortic Stent Graft System ("Castor™") on Vascular News, an important source for news, views, comment and controversy in the vascular industry.
MicroPort® Endovascular Completed Enrollment of Pre-market Clinical Trial for Reewarm18
20 Dec 2014
MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular") recently completed the enrollment of pre-market clinical trial for its first-generation Reewarm18 Peripheral Balloon Dilation Catheter ("Reewarm18") to prove its safety and efficacy.
Castor™ was Selected as Key Project of National Program
30 Nov 2014
Castor™ Thoracic Branch Stent-Graft System ("Castor™"), an endovascular device developed by MicroPort Endovascular (Shanghai) Co, a subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort"), was successfully selected as one project of the National Key Technology R&D Program for China's 12th Five-Year Plan in November.
First Clinical Implantation of Ultra Low Profile Completed
13 Nov 2014
Ultra Low Profile AAA Stent-Graft System ("Ultra Low Profile"), an endovascular device in-house developed by MicroPort Endovascular (Shanghai) Co ("MicroPort Endovascular"), a subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort"), recently completed its first clinical implantation in Shanghai-based Zhongshan Hospital.
CRONUS™ Stent Graft System In Surgical Operation won the second prize of Pudong Scientific and Technological Achievements.
05 Oct 2014
Shanghai, China – 30 October, 2014 - CRONUS™ Surgical Stent Graft System ("CRONUS™"), an endovascular device of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort"), was recently granted the second prize of scientific and technological achievements by Pudong New Area Science and Technology Commission of Shanghai Municipality.
Hercules™ Balloon Inflation Catheter Received CFDA Certificate
17 Oct 2013
Recently, Hercules™ Balloon Inflation Catheter, independently developed by MicroPort and its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd., received certificate from China Food and Drug Administration (CFDA). Hercules™ Balloon Dilatation Catheter literary filled the gap in the domestic-made large balloon market and broke the dependence on the foreign-made products. The device effectively addresses the endoleak during the endovascular treatment for the aortic aneurysm or dissection.
Hercules™-B Bifurcated Stent-graft and Delivery System Honored with 2013 National Key New Project
28 Sept 2013
Recently, MicroPort's Hercules™-B Bifurcated Stent-graft and its delivery system were honored with 2013 National Key New Project. It is the 5th consecutive years in which MicroPort has receive the certificate.
About us
News
Products
Investor Relations
Telephone:(86) (21) 38139300
Address:Building #1,3399 Kangxin Rd., SIMZ Century Medicine Park, Shanghai201318,P.R. China
Fax:(86) (21) 33750026
©Copyright 2002-2025, Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd.
Internet Drug Information Service Qualification Certificate No.: (Hu) - Non-operating -2024-0188
Website record/ license No.：沪ICP备14048493号-1 
HGWA Bei No.31011502014536
The registered trademarks of “微创", "MicroPort" and"
" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd., they have been authorized to be used by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., and no other party shall use such trademarks without prior written permission thereof.
<i id='abbd0'><strike id='dde0c'><tt id='4a7b7'><pre id='e5f13'></pre></tt></strike></i>